Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease by Metzger, Corinne E. et al.
Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic  
kidney disease 
Corinne E. Metzger1*, Elizabeth A. Swallow1*, Alexander J. Stacy1, Samantha P. Tippen1, 
Max A. Hammond1, Neal X. Chen 2, Sharon M. Moe1,2,4, and Matthew R. Allen1,2,3,4
*Co-First Authors
1Department of Anatomy, Cell Biology, Physiology, Indiana University School of Medicine, 
Indianapolis IN, United States 
2Department of Medicine – Division of Nephrology, Indiana University School of Medicine, 
Indianapolis IN, United States. 
3Department of Biomedical Engineering, Indiana University Purdue University of 
Indianapolis, Indianapolis, IN, United States. 
4Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. 
Corinne Metzger, Elizabeth Swallow, Alexander Stacy, Samantha Tippen, Max Hammond, 
Neal Chen, Sharon Moe, and Matthew Allen declare that they have no conflicts of interest 
related to the presented work.
Send Correspondence to: 
Matthew R. Allen, PhD 
Dept. of Anatomy, Cell Biology, Physiology, MS 5035 
Indiana University School of Medicine 
635 Barnhill Dr. 
Indianapolis, IN 46202 
Email: matallen@iu.edu 
_______________________________________________
This is the author's manuscript of the article published in final edited form as:
Metzger, C. E., Swallow, E. A., Stacy, A. J., Tippen, S. P., Hammond, M. A., Chen, N. X., Moe, S. M., & Allen, M. R. 





Purpose: Chronic kidney disease (CKD) patients have a high incidence of fracture due in 
part to cortical porosity. The goal of this study was to study cortical pore infilling utilizing two 
rodent models of progressive CKD. 
Methods: Exp 1: Female C57Bl/6J mice (16-week-old) were given dietary adenine (0.2%) to 
induce CKD for 10 weeks after which calcium water supplementation (Ca-H2O; 1.5% and 
3%) was given to suppress PTH for another 4 weeks. Exp 2: Male Cy/+ rats were aged to 
~30 weeks with baseline porosity assessed using in vivo µCT. A second in vivo scan 
followed 5-weeks of Ca-H2O (3%) supplementation. 
Results: Exp 1: Untreated adenine mice had elevated blood urea nitrogen (BUN), 
parathyroid hormone (PTH), and cortical porosity (~2.6% porosity) while Ca-H2O lowered 
PTH and cortical porosity (0.5-0.8% porosity). Exp 2: Male Cy/+ rats at baseline had variable 
porosity (0.5% - 10%), but after PTH suppression via Ca-H2O, cortical porosity in all rats was 
lower than 0.5%. Individual pore dynamics measured via a custom MATLAB code 
demonstrated that 85% of pores infilled while 12% contracted in size.  
Conclusion: Ca-H2O supplementation causes net cortical pore infilling over time and 
imparted mechanical benefits. While calcium supplementation is not a viable clinical 
treatment for CKD, these data demonstrate pore infilling is possible and further research is 
required to examine clinically relevant therapeutics that may cause net pore infilling in CKD. 
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Skeletal fragility in chronic kidney disease (CKD) is common. End-stage renal disease 
(ESRD) patients have a 4-fold increased risk of fracture compared to their age matched non-
CKD counterparts [1]. Fractures in CKD patients not only contribute to reduced mobility and 
quality of life, but fractures are also associated with a significantly greater rate of mortality in 
CKD patients compared to patients with normal kidney function [2] [3] [4] [5] [6] [7]. With one 
in seven people in the United States estimated to have some degree of CKD, preventing or 
reversing skeletal fragility in CKD would have significant public benefit [2] [8].  
As the disease progresses, CKD patients often develop a triad of clinical manifestations 
known as chronic kidney disease mineral bone disorder (CKD-MBD) including biochemical 
abnormalities, vascular calcifications, and bone deterioration [9] [10] [11]. Unlike other forms 
of bone loss which primarily impact trabecular bone, bone deterioration in CKD 
predominately affects the cortical compartment of bone in the form of cortical porosity. Since 
cortical bone is important for the mechanical and structural integrity of bone, cortical porosity 
contributes significantly to increased fractures seen in CKD patients [12] [13]. Reducing 
cortical porosity may be key in preventing skeletal fragility and improving bone health in CKD 
patients.  
Reduction of cortical porosity can occur through several mechanisms including suppressing 
new pore formation, suppressing of pore growth, or infilling of pores with a combination likely 
having greatest benefit on overall porosity. Previous work in animal studies has 
demonstrated that prevention of cortical pores is possible through suppression of PTH via 
calcium water supplementation (Ca-H2O) [14] [15]. It remains largely unknown whether 
cortical pore infilling is possible and, if so, what conditions are ideal to promote infilling. We 
aimed to explore this question with two animal models of CKD: 1) adenine-induced CKD in 
mice and 2) the Cy/+ rat with spontaneous development of polycystic kidney disease. Both 
models develop characteristics of clinical CKD with impaired kidney function as well as high 
circulating PTH and cortical porosity [16] [17] [15]. Previously, we have demonstrated that 
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Ca-H2O is a suppressor of PTH and that it prevents the development of cortical pores. In 
both models in this study, treatment initiation with Ca-H2O occurred after the development of 
porosity. Importantly, this is in contrast to our previous work which has focused on cortical 
pore prevention with treatment initiation (Ca-H2O) in the early stages of CKD progression 
prior to the formation of cortical pores [14] [15].We hypothesized that PTH suppression via 
calcium water supplementation would reduce porosity in female adenine-induced CKD mice 
and improve mechanical properties of bone. Secondly, utilizing the male Cy+ model, we 
hypothesized that cortical porosity would decrease after calcium water supplementation and 






Animals: 15-week-old female C57Bl/6J mice (Jackson Laboratories, Bar Harbor, ME, USA; 
JAX #000664; n=96) were group housed 4/cage in an institutionally approved animal facility. 
After a one-week acclimation, all control mice were put on a purified casein-based diet with 
an adjusted calcium and phosphorous ratio (0.9% P, 0.6% CA). All adenine-induced CKD 
mice were put on the same casein-based diet with the addition of 0.2% adenine (Envigo 
Teklad Diets, Madison, WI, USA). All treatment and control groups (n=10-12/group) are 
described in Figure 1a. Previous studies demonstrated that adenine ingestion in mice 
results in progressive kidney impairment including elevated creatinine, blood urea nitrogen, 
and parathyroid hormone [18] [19] [20] [21]. After six weeks on the adenine diet, all adenine 
mice were switched back to the control diet as we and others have demonstrated that an 
induction period of adenine is sufficient to result in continued elevations in BUN and PTH in 
rodents [21] [22] [23] [24] [25]. Ten weeks after initiation of diets, a group of control and 
adenine mice were anesthetized via inhaled vaporized isoflurane and euthanized via 
thoracotomy and exsanguination. Remaining control and adenine groups were divided into 
three groups – standard drinking water (Control and Adenine), 1.5% calcium gluconate 
drinking water (Con+1.5% and Ad+1.5%), and 3% calcium gluconate drinking water 
(Con+3% and Ad+3%). Calcium water supplementation (Ca-H2O) was provided continuously 
for four weeks followed by euthanasia, 14 weeks after diet initiation. Kidney and right femurs 
were fixed in 10% neutral buffered formalin. Left femurs were frozen in phosphate buffered 
saline-soaked gauze. All animal procedures were approved by the Indiana University School 
of Medicine Institutional Animal Care and Use Committee prior to the initiation of any 
experimental protocols. 
Serum biochemistries: Cardiac serum collected at time of euthanasia was used to 
measure serum blood urea nitrogen (BUN) via colorimetric assay (BioAssay Systems, 
Hayward, CA, USA). Serum 1-84 parathyroid hormone was measured via ELISA 
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(Immunotopics Quidel, San Diego, CA, USA) with an intra-assay coefficient of variation of 
2.4-5.6% and an inter-assay coefficient of variation of 5.5%.  
Ex vivo Micro-Computed Tomography of the Femur: Right distal femurs were scanned 
on a SkyScan 1172 (Bruker, Billerica, MA, USA) with a 0.5 aluminium filter and a 6 µm voxel 
size. Cortical bone was analyzed in the femur from 5 slices located ~2.5 mm proximal to the 
most proximal portion of the distal growth plate. Cortical area, cortical thickness, cortical 
porosity and pore number were assessed from this site. Cortical porosity was determined by 
assessing total void volume between the periosteal and endosteal surfaces, presented as a 
% of overall cortical volume. Pore number was determined as the number of pores per mm2 
of cortical bone. 
Ex vivo Micro-Computed Tomography of the Kidney: Fixed kidneys were scanned on a 
SkyScan 1176 (Bruker, Billerica, MA, USA) with no filter and a 9 µm voxel size. A 0.5 mm 
region of interest was selected at the middle of the kidney for assessment of crystal volume/ 
kidney volume within the ROI. 
Three-point Bending of the Femur: Frozen left whole femurs were scanned on a SkyScan 
1176 (Bruker, Billerica, MA, USA) with a 0.5 aluminium filter and 9 µm voxel size for 
assessment of mid-shaft cortical geometry. The midshaft region was selected by measuring 
half the length of the full bone from the CT scan. After thawing, samples underwent a three-
point-bend test with a bottom span of 6 mm and the central fixture located approximately at 
the longitudinal mid-point of the femur (Model 500lbs Actuator with R Controller, Test 
Resources, Shakopee, MN, USA). All samples were tested until failure with the anterior 
surface in compression. Samples were kept hydrated with PBS and loaded at 2mm/minute 
to collect force-displacement data. Mechanical outcome parameters were calculated in a 
custom MATLAB script using the force-displacement data and cortical geometry parameters 
generated from a single mid-shaft (1/2 total length) slice as previously described [14] [15] 
[26] [27]. All data collected used standard nomenclature.    
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Statistical Analyses: Data from 10-week control and adenine mice were compared via a t-
test. All data from the 14-week timepoint except for kidney crystals were analyzed as a 2x3 
factorial ANOVA (disease-by-calcium water supplementation) and all main effects and 
interaction effects noted. If the model 2x3 ANOVA was statistically significant (p<0.05), an 
all-groups Duncan post hoc analysis was applied to determine differences between groups. 
Kidney crystals were analyzed via a one-way ANOVA at the 14-week timepoint between all 
adenine groups due to the lack of crystals in all control kidneys. All statistical analyses were 
completed with IBM SPSS Statistics 26 (IBM, Armonk, NY, USA). Data are represented as 
mean ± standard deviation. 
Experiment 2 
Animals.  
Male Sprague Dawley Cy/+ rats (n=6) were placed on a casein-based diet with adjusted 
calcium and phosphorous ratio (0.6% and 0.9%, respectively) at 18 weeks of age. In-vivo 
µCT scans were performed for baseline measures of porosity at 30 weeks of age. Previous 
longitudinal data from our lab has shown that cortical porosity often develops around 30 
weeks of age and, in some cases, severe cortical porosity is seen by 35 weeks of age [28]. 
All animals (n=6) were then provided calcium supplementation via 3% calcium gluconate 
drinking water (Ca-H20) for 5 weeks (Figure 1b). In this study our goal was to investigate 
cortical infilling, therefore, Ca-H2O commenced after the development of cortical pores [28]. 
At 35 weeks of age animals underwent a second µCT scan and then were anesthetized via 
inhaled vaporized isoflurane and euthanized via thoracotomy and exsanguination. All study 
procedures were approved by the Indiana University School of Medicine Institutional Animal 
Care and Use Committee before the commencement of any experiments. 
Serum biochemistries. Blood was collected before in vivo baseline and endpoint scans 
using tail vein collection. Blood was spun down for 10 minutes in a centrifuge (LW Scientific 
Combo M24 Centrifuge, Lawrenceville, GA, USA) at ~12,000 RPM to collect approximately 
200µL of serum for biochemistry assays. Serum was used for analysis of blood urea 
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nitrogen (BUN) by colormetric assay (BioAssay Systems) and intact parathyroid hormone 
(iPTH) by ELISA (Immunotopics). 
In-vivo Micro-Computed Tomography of the distal tibia. Under isoflurane anaesthesia, 
rats were placed supine in the bed of the Skyscan 1176 µCT (Bruker, Billerica, MA, USA). 
Right distal tibias were secured in a polystyrene holder with the tail and contralateral foot 
adjusted to be outside the field of view to assure clear isolation of the right distal tibia as 
previously described [28]. All scans were performed at 9µm voxel resolution, 1mm Al filter, 
0.5° rotation step, and no frame averaging. Each scan lasted approximately 10 minutes.  
The µCT scans for each animal were first manually registered in manufacturer supplied 
software (DataViewer version 1.5.2.4, Bruker) to align the scans, followed by a computerized 
approach using a pseudo 3D registration strategy, 50 (pixel) shift range, and a rotation range 
of 25 in degree. Registered images were used to define three volume of interests (VOIs) 
located at 4mm, 4.5mm, and 5mm’s distal to the tibia-fibular junction (TFJ) to measure 
cortical porosity using manufacturer supplies software (CTAn version 1.14.3, Bruker). Each 
VOI was comprised of 5 consecutive slices. For each slice, the cortical bone was isolated 
using a hand drawn ROI to demarcate the endocortical and periosteal surfaces. These 
images of isolated cortical bone were processed further using MATLAB. 
 
Custom MATLAB code tracking individual pore tracking. All CT images, across all 
animals and VOIs, were imported into a custom MATLAB (Matrix Laboratory, MathWorks) 
script designed to track pores over time through a coordinate based (x, y, and z) identifying 
system. The script first defines an optimal threshold (using the Otsu method) across all 
animals and slices to use for segmentation of bone from void. A pore was defined as an area 
with more than 5 connected pixels in 2D space (486 um2) so as to exclude background noise 
and vascular channels. To match pores in repeat scans, the script indexed each pore via a 
spatial grid allowed for pixel matching and relationship determination. Pores were indexed 
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based on whether they existed just in the baseline image, both baseline and endpoint 
images, or just endpoint images. Pore relationships were established by determining which 
pores shared pixels. Four basic pore relationships were determined to capture some basic 
dynamic pore activities:  
1. developed - present in endpoint image, but not in baseline image  
2. expanded - present in both baseline and endpoint images, but the pore is larger at 
endpoint than at baseline  
3. filled – present in baseline image, not in endpoint image 
4. contracted – present in both baseline and endpoint images, but the pore is smaller at 
endpoint than at baseline  
The pores were captured as changing dynamic entities when the net change in pixel size 
was greater than 1 pixel. This permitted the designation into appropriate pore category. If a 
pore was unchanged from baseline to endpoint it was considered ‘static’. For each animal, 
data is presented as cumulative totals. 
Statistics. Data from baseline and endpoint measures were compared using a paired t-test 
with statistical difference defined as p<0.05. All statistical analyses were completed with 
SPSS Statistics 26 (IBM). Data are represented as mean ± standard deviation. 
RESULTS 
Experiment 1 
Serum blood urea nitrogen was elevated in adenine mice indicating the presence of kidney 
disease. At 10 weeks, BUN was higher in adenine vs. control (p<0.0001). At 14 weeks, there 
was a main effect of disease (p<0.0001), Ca-H2O (p=0.001), and a disease-by-Ca-H2O 
interaction (p<0.0001). All adenine groups had higher BUN than control groups. Ca-H2O 
increasing BUN in adenine groups compared to untreated adenine. Both Con+1.5% and 
Con+3% groups had lower BUN than untreated control (Figure 2a). Kidney crystals were 
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present, but they were not different across adenine groups at the 14-week time point 
(p=0.143; Figure 2b). 
Serum PTH was higher in adenine mice at 10 and 14 weeks while Ca-H2O suppressed PTH 
in 14-week adenine mice. At 10 weeks, PTH was higher in adenine vs. control (p=0.002). At 
14 weeks, there was a main effect of disease (p=0.034), a main effect of Ca-H2O 
(p<0.0001), and a disease-by-Ca-H2O interaction (p=0.003). At the 14-week timepoint, the 
untreated adenine group had higher PTH than all other groups with the Ad+1.5% and 
Ad+3% groups not statistically different from any of the control groups (Figure 3a). 
Ca-H2O resulted in lower cortical porosity in adenine mice after 4 weeks of treatment. At 10 
weeks, adenine mice had no differences in cortical area (p=0.601), but lower cortical 
thickness versus controls (p<0.0001). At this time point, cortical porosity was also higher in 
adenine mice vs control (p<0.0001; Figure 3b). Pore number was also higher in adenine 
mice compared to controls (p<0.0001; Table 1). At 14 weeks, there was no effect on cortical 
area (p=0.324), but there was statistical differences in cortical thickness (p<0.0001) with a 
main effect of disease (p<0.0001) and a main effect of Ca-H2O (p=0.001), but no interaction 
effect (p=0.594). Cortical thickness was lowest in untreated adenine mice followed by 
adenine mice with calcium water supplementation with Ca-H2O-treated control mice having 
the highest cortical thickness (Table 1). For cortical porosity at 14-weeks, there was a main 
effect of disease (p<0.0001), a main effect of Ca-H2O (p<0.0001), and a disease-by-Ca-H2O 
interaction (p<0.0001). At the 14-week timepoint, the untreated adenine group had higher 
porosity than all other groups. Calcium-treated adenine mice had porosity values not 
different from control mice (Figure 3b; Figure 3c). Additionally, there was a main effect of 
disease, a main effect of Ca-H2O, and an interaction effect on pore number at 14-weeks 
(p<0.0001 for all). Pore number was highest in untreated adenine with Ad+1.5% lower than 
untreated adenine and Ad+3% not different from any of the control groups (Table 1).  
Ca-H2O improved ultimate force in adenine-induced CKD mice compared to untreated 
adenine mice. At 10 weeks, adenine mice had lower ultimate force compared to control mice 
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(p=0.009; Table 1) however, post-yield displacement (p=0.618), stiffness (p=0.05), total 
work (p=0.085), and toughness (p=0.614) were not statistically different (Table 1). At 14 
weeks, untreated adenine mice exhibited the lowest ultimate force of all groups with a main 
effect of disease (p=0.008) while Ca-H2O led to higher ultimate force in both control and 
adenine-treated mice (main effect of Ca-H2O p=0.001; Table 1); however, there was no 
interaction effect (p=0.127). Post-yield displacement was not different between all groups 
regardless of treatment at 14 weeks (p=0.426). Stiffness showed a disease-by-Ca-H2O 
interaction effect (p=0.003). All adenine groups displayed lower stiffness compared to 
Con+3%, with a main effect of disease (p<0.0001). Ca-H2O had no main effect on stiffness 
(p=0.103) despite the Con+3% group having the highest stiffness. Stiffness was not different 
between all adenine groups. At 14 weeks, all control groups had higher total work compared 
to untreated adenine mice with a main effect of disease (p=0.006), but no disease-by-Ca-
H2O interaction effect (p=0.096) or main effect of Ca-H2O (p=0.893). Toughness was not 
different between all groups regardless of disease or treatment at 14 weeks (p=0.425) 
(Table 1).    
Experiment 2 
Ca-H2O suppresses PTH without altering BUN. During the 5-week treatment phase, BUN in 
Cy/+ rats was not different from baseline to endpoint (p=0.149; Figure 4a). At baseline all 
rats had PTH values ranging between 500-2500 pg/mL, but following Ca-H2O, PTH values 
ranged between ~30-80 pg/mL (p=0.012; Figure 4b).  
Cortical porosity decreases after a 5-week period of Ca-H2O due to individual pore infilling. 
Cortical porosity in distal tibia of the 6 animals at baseline ranged between 0.5% to 10.1%, 
illustrating the heterogeneity of disease within the model (Figure 5a and 5b). After 5 weeks 
of Ca-H2O, cortical porosity was less than 1% in all animals (p=0.163; Figure 5a). Individual 
pore tracking demonstrated that the predominate pore action during the 5-week treatment 
period was complete pore infilling (85%), while 12% of pores got smaller (contracted), and 
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3% of pores were newly developed; no pores were quantified as getting larger (expanding) 
and only one pore was static (no change in pore size) from baseline to endpoint (Figure 5c). 
 
DISCUSSION 
Utilizing two animal models of CKD, our studies demonstrate that cortical porosity is 
reduced after suppression of PTH via calcium water supplementation. Additionally, we were 
able to track individual pores over time, demonstrating that PTH suppression resulted in pore 
infilling and prevention of new pore formation. Notably, we allowed cortical pores to develop 
in both of our models prior to the initiation of treatment unlike previous studies that utilized 
calcium water supplementation to prevent pore formation by initiating treatment in the early 
stages of the disease progression [15] [14]. Overall, these data show that cortical pore 
reduction/infilling is possible in animal models of CKD. This research creates a foundation 
for future research to test and explore clinically relevant therapies in a CKD population which 
may also have the potential to cause net pore infilling.  
 Adenine-induced CKD and the Cy/+ rat model are both clinically relevant as they 
model the human characteristics of CKD-MBD with the progressive development of elevated 
PTH and cortical porosity. Utilizing the high resolution of HR-pQCT scans, Nickolas, et al., 
quantified the rapid development of cortical porosity averaged per year in CKD patients and 
found cortical deterioration was predicted by serum PTH [13]. In both the Cy/+ rat and 
adenine-induced CKD in mice, we have demonstrated progressive development of cortical 
porosity over time and that the highest levels of cortical porosity are concurrent with high 
PTH [21] [28]. It is important to note that the structure of the cortical bone varies between 
rodents and humans due to the lack of osteons in rodents; however, cortical porosity 
develops in both humans and rodents indicating the potential for similar mechanisms despite 
structural differences.  
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In both preclinical and clinical settings, little is known about the development of 
cortical porosity in CKD other than correlations with PTH. We have previously seen that 
rodents (Cy/+ rat) placed on calcium water supplementation prior to the development of 
cortical porosity never form pores [15] [14] likely demonstrating the importance of PTH in the 
development of porosity. While little is known about the mechanisms that lead to the 
development of cortical pores in CKD, even less is known about what happens to those 
pores once they form and if porosity can be reversed.  
In adenine-induced CKD mice, cortical porosity measured at the distal 1/3 femur was 
2.7-3.1% at both 10 weeks and 14 weeks after the initiation of the adenine diet (Fig. 3b). At 
14 weeks, after 4 weeks of either 1.5% or 3% calcium water supplementation, cortical 
porosity was 0.3-0.8%, approximately a 70-90% reduction compared to the levels in 
untreated animals (Fig. 3b). In vivo longitudinal scans of Cy/+ rats showed similar effects on 
cortical porosity at the distal tibia after calcium water supplementation, with porosity of 
animals averaging 3.1% prior to treatment and 0.5% after calcium water supplementation. 
Given that we tracked pores longitudinally within the same animal we can conclude that 
cortical pores infilled and new pore formation/expansion was suppressed. In both animal 
models, the reduction in cortical porosity coincided with suppression of PTH. These studies 
demonstrate that cortical pore reversal is possible in rodent models. Further research is 
required to understand if or to what degree cortical pores in human bone can infill.  
The presence of cortical porosity is associated with reductions in bone mechanical 
properties in preclinical models [14] [15] and in human bone samples [29] as well as 
associations with fracture in clinical studies [30] [31] [32] [33]. Thus, the goal of pore infilling 
would be to normalize mechanical properties and reduce fracture risk. After 14 weeks of 
adenine-induced CKD, untreated adenine mice had 11% lower ultimate force versus 
untreated controls. Compared with aged-matched untreated adenine mice, groups treated 
with calcium water supplementation for 4 weeks had 70-90% lower cortical porosity and 14-
18% higher ultimate force. It is important to note that our porosity measures were in the 
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distal third of the femur while our mechanical assessment was at the midshaft thus we 
cannot directly conclude the effects were mediated by porosity. Calcium-water 
supplementation also resulted in higher cortical thickness in treated adenine mice vs. 
untreated adenine mice which likely also contributes to improved mechanical properties. 
Given the fact that matrix properties are often compromised in CKD, the absence of 
complete normalization of mechanical properties is not a complete surprise – yet the fact 
that there is a beneficial effect on bone strength is encouraging. Additionally, we cannot 
completely determine if this is an effect of having fewer cortical pores or is an independent 
effect of calcium water supplementation since control calcium water-treated mice also had 
some increases in ultimate force. However, our results show that 1.5% calcium 
supplementation has minimal effect on ultimate force on control mice (0.4% higher vs. 
untreated controls) whereas, adenine mice on the same treatment demonstrated greater 
increases on ultimate force (18% higher vs. untreated adenine). We hypothesize the large 
differences between adenine and control groups with 1.5% calcium water supplementation is 
due to pore reduction. Future work will need to further address the impact of pore reversal 
on mechanical properties of bone.  
Longitudinal cortical porosity has been previously measured in both human studies 
and animal models [13] [28]; yet, studies investigating the dynamics of individual pores over 
time are lacking. Cortical porosity measures over time could be affected in many ways that 
are not necessarily reflected if total porosity is the only variable assessed. For example, one 
large pore could fill in modestly while multiple new smaller pores may form, leaving overall 
porosity unchanged; yet, it is unknown how these differences in the size and number of 
pores may impact overall mechanical properties. Our approach in Experiment 2 with the 
Cy/+ rat model, provides a unique insight into individual cortical pore dynamics. Unlike 
cortical porosity that only quantifies porosity within a given VOI or slice, our approach of 
individual pore tracking permits us to measure the change of each pore, individually, over 
time. This showed, for example, that in the Cy/+ rat with the highest porosity at baseline 
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(10.1%), most pores filled in after treatment, yet a small number of pores also developed 
(Figure 5C). This technological approach to individual pore tracking has the potential to 
better inform dynamics of cortical porosity over time using CT in both pre-clinical and 
perhaps clinical studies. 
These results provide proof-of-concept data about pore infilling – the first of many 
steps. Further research will be required to determine whether the effects of cortical pore 
reduction and pore infilling as seen in this study stimulated  by calcium water 
supplementation is a result of extra exogenous calcium in the circulation, suppression of 
PTH, or a combination of exogenous calcium and PTH suppression. Furthermore, calcium 
water supplementation is not a clinically viable treatment since CKD patients are already at 
an increased risk of extracellular and vascular calcification. In our current study with mice, 
BUN was higher in adenine mice with calcium water supplementation which could allude to 
worsening of kidney disease in this model as well. Despite the treatment method of calcium 
water being a clear limitation for clinical translatability, this study presents unique longitudinal 
data showing the refilling of individual pores which is has conceptual novelty. Therefore, 
future studies must examine whether PTH suppression is critical for cortical pore infilling to 
occur as well as discover what clinically relevant therapies are available that can stimulate 
pore infilling.  
The tissue-level mechanisms underlying pore formation and infilling in the context of 
CKD are largely unknown. Pores can be stimulated in rodent models via administration of 
PTH [34] and in female rats fed a low calcium diet during lactation [35] [36]. In lactation 
models, there is evidence of bone formation on pore surfaces [36]. While the dynamic nature 
of osteoclast and osteoblast activity on pore surfaces in rodents is sometimes called intra-
cortical remodeling [35] [36], it is critical to differentiate this from intra-cortical remodeling in 
larger mammals within the more normal primary/secondary osteonal structure of cortical 
bone. In rodents, remodeling does not occur within the cortex under normal physiological 
conditions. Nonetheless, it is noteworthy that both rodents and humans develop cortical 
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porosity in CKD which indicates the mechanisms potentially may not be linked to 
physiological intra-cortical remodeling. In other conditions, like aging, cortical porosity 
develops due to intracortical remodeling in both rodents and humans [37] [38]. This further 
demonstrates that differences in cortical bone structure may not preclude animal models 
from having value for studying mechanisms of cortical porosity development and infilling. 
Further research will need to address the mechanism inducing pore infilling in rodents.  
Limitations of our two experiments include the use of only male Cy/+ rats and only 
female adenine mice. While sex differences in cortical pore dynamics are of interest for 
future work, our use of a single sex in each study together still demonstrate that 
reduction/infilling of cortical pores occurs with calcium water supplementation in two 
progressive models of CKD. Furthermore, we were prevented from doing longitudinal pore 
tracking in mice due to the limitations of resolution of in vivo µCT relative to pore sizes in 
mice. We are not able to directly determine if cortical porosity was responsible for the 
mechanical benefit in the mouse study as our assessment of porosity was not directly at the 
site of testing.  Additionally, as mentioned above, our use of calcium water supplementation 
is of itself not clinically relevant, however, as a suppressor of PTH, it provides a proof-of-
concept that cortical pores can infill. Future studies will also need to address the 
mechanisms of cortical pore infilling utilizing techniques like dynamic histomorphometry to 
track formation over time within pores. Finally, there was a pattern of difference between 10 
and 14 week adenine mice that hint at reduced BUN at the later timepoint. If kidney function 
improved over time this would complicate the interpretation of the model, although it is noted 
that both porosity and PTH remain well above normal at the 14 week timepoint. 
In conclusion, our work demonstrates that cortical pores that develop in the setting of 
CKD are capable of infilling in rodent models. Future work should focus on what therapies 
are best suited to stimulate pore infilling and whether this is possible in humans. Ideally, 
determining the best therapeutic strategy to both infill existing pores as well as prevent new 
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pores from developing may provide the best scenario to improve bone health in CKD 
patients through the reduction in skeletal fragility.  
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Table 1. Cortical bone parameters measured from the distal 1/3 femur and mechanics 
properties from 3-pt-bend test of the contralateral femur of adenine-induced CKD mice. 
Group values not sharing the same superscript letters are statistically different (p<0.05 from 
a Student’s t-test for 10-week values and from a Duncan post-hoc following a 2X3 ANOVA 
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Figure 1. Experimental design for experiment 1 (adenine-induced CKD in mice) and 
experiment 2 (Cy/+ rat). Black lines represent Control groups while and grey lines represent 
CKD (Exp 1 = adenine, Exp 2 = Cy/+). Thick grey lines indicate induction period of 0.2% 
adenine diet in adenine-induced CKD mice. Thin lines represent times on control diet. Solid 
lines represent untreated periods and dashed lines are periods treated with calcium water 
supplementation (1.5% or 3%). 
Figure 2. Serum blood urea nitrogen (BUN) and kidney crystal assessment in adenine-
induced CKD mice (n=10-12/group). A) Serum BUN was higher in adenine vs. control at 10 
weeks. At 14 weeks, serum BUN was lower in both Con+1.5% and Con+3% compared to 
untreated Con while Ca-H2O supplementation increased BUN in adenine groups. 
#Indicates 
statistical difference in t-test at 10 weeks. At 14 weeks, bars not sharing the same letter are 
statistically different. B) Kidney crystals were present in adenine mice with no statistical 
differences due to Ca-H2O treatment. 
Figure 3. Serum parathyroid hormone (PTH) and cortical porosity at the distal 1/3 femur in 
adenine-induced CKD mice (n=10-12/group). A) Serum PTH was higher in adenine mice at 
10 weeks. At 14 weeks, the untreated adenine group had higher PTH than all other groups. 
#Indicates difference in t-test at 10 weeks (p<0.05). *Indicates statistically different from all 
other 14-week groups (p<0.05). B) At 10 weeks, cortical porosity was higher in adenine vs. 
control mice. At 14 weeks, the untreated adenine group had higher cortical porosity than Ca-
H2O-treated adenine groups and all control groups. 
#Indicates difference in t-test at 10 
weeks (p<0.05). *Indicates statistically different from all other 14-week groups (p<0.05). C) 
Representative images of cortical bone in control and adenine-induced CKD mice.  
Figure 4. Blood urea nitrogen (BUN) and parathyroid hormone (PTH) serum measures at 
baseline (30 weeks) and endpoint (35 weeks) in male Cy/+ rats (n=5). A) BUN is not 
different between baseline and endpoint. B) PTH significantly declined at endpoint due to 5 
weeks of Ca-H2O treatment.  * Indicates difference in a paired t-test (p<0.05). 
25 
 
Figure 5. Cortical porosity of the distal tibia before (baseline) and after (endpoint) calcium 
water supplementation via longitudinal in vivo µCT scans in male Cy/+ rats (n=6). (A)  
Quantification of cortical porosity with representative images shown in (B) for all animals 
used in the study. Note the heterogeneous development of cortical pores at baseline in this 
Cy/+ model with some CKD rats displaying low levels of cortical pores. There are no 
statistical differences in total porosity (repeated measures t-test analysis). (C) Individual pore 
tracking across all six animals quantified by the number of pores at baseline and endpoint as 
well as the number of pores completing a dynamic action (filled, contracted, developed, 
expanded). There were significantly less pores at the endpoint compared to baseline 
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 CKD-induced cortical porosity was reduced in rodent models after PTH suppression. 
 Reducing cortical porosity improves bone mechanics in mice with CKD. 
 Individual pore tracking over time documents pore infilling in CKD animals. 
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